QBM 001

Drug Profile

QBM 001

Alternative Names: ASD-002-ASDERA/Q Biomed; ASD002; ASD02; Mefenamic acid prodrug - Q-Biomed; QBM-001

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ASDERA
  • Developer ASDERA; Q BioMed
  • Class Antimigraines; Antipyretics; Fenamates; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Migraine

Most Recent Events

  • 19 Oct 2017 Q BioMed intends to complete preclinical studies in January 2018
  • 20 Sep 2017 Q Biomed plans a phase II/III trial for Migraines and Seizers in USA (Q Biomed pipeline, September 2017)
  • 19 Sep 2017 Q BioMed and Sphaera enter into partnership for QBM 001 for paediatric autism spectrum disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top